AzTrials
AzTrials

Tranexamic Acid (TXA)Phase 4NCT05705336

Clinical Trial Analyzing the Efficacy of Oral Administration of Tranexamic Acid in Spine Surgery.

A Phase 4 study testing Tranexamic Acid Oral Product in people with Tranexamic Acid (TXA) and Prospective Study, run by Alejandro Reyes Sánchez at 1 site in Mexico.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Study design: Randomized control trial Purpose: Evaluate the efficacy of oral administration of tranexamic acid (TXA) in spine surgeries to achieve blood loss reduction. Methods. A total of 60 patients undergoing major surgery of the spine, were randomly assigned into 2 groups. Read more about this study

Who is it for?
Ages 40 to 70 years
What is being tested?
Tranexamic Acid Oral Product
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteMexico
Study dates
1 Jan 2021to 1 Jan 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients of 40-70 years
  • Patients undergoing major surgery (it was defined as "surgeries involving the intervention of more than 4 levels of the thoracolumbar spine, and with a diagnosis of failed back surgery or, deformities in the spine")
  • Complete data
  • Agree to sign the informed consent

Who cannot join

  • Patients excluded were those with low preoperative hemogram values (Hb <10mg/dL, low platelet counts (<100 x 109/L)
  • Bleeding disorders, coagulopathies
  • Intake of contraceptives or anticoagulant medication
  • Active thromboembolic disease (deep venous thromboembolism, chronic venous insufficiency, chronic thromboembolism)
  • Fibrinolytic disorders secondary to consumption coagulopathy
  • History of thromboembolic or coronary disease
Show all 13Show fewer
  • History of seizure
  • Liver failure
  • Dyslipidemia
  • Congenital coagulopathies (Von Willebrand Disease, Hemophilia A and B)
  • Acquired coagulopathy (Vitamin K deficiency, disseminated intravascular coagulation)
  • Thrombocytopenic purpura
  • Patients in whom postsurgical hemoglobin was not available, or patients who accidentally removed the drain or had leaks were eliminated from the study

Trial locations and contacts

1 site in 1 country.

Mexico1 site
  • Alejandro Reyes Sánchez

    Mexico City, 14389

Other trials in Mexico

About this study

Official title: Prospective Randomized Controlled Trial Analyzing the Efficacy of Oral Administration of Tranexamic Acid in Spine Surgery.

Study design: Randomized control trial Purpose: Evaluate the efficacy of oral administration of tranexamic acid (TXA) in spine surgeries to achieve blood loss reduction.

Methods. A total of 60 patients undergoing major surgery of the spine, were randomly assigned into 2 groups. Group 1 was assigned as the control group and the other one included oral administration of tranexamic acid 2 hours prior to surgery. Outcomes measures included intraoperative blood loss, postoperative blood loss, hematological parameters, blood transfusion needed, and surgical complications.

Read the detailed description

The study design is a prospective randomized control trial done in a single institution from 2021 to 2022. Approval from the institutional ethics committee was obtained for the study (number 04/21). Major surgery was defined as "surgeries involving the intervention of more than 4 levels of the thoracolumbar spine, and with a diagnosis of failed back surgery or, deformities in the spine". Patients excluded were those with low preoperative hemogram values (Hb <10mg/dL, low platelet counts (<100 x 109/L), bleeding disorders, coagulopathies, intake of contraceptives or anticoagulant medication, active thromboembolic disease (deep venous thromboembolism, chronic venous insufficiency, chronic thromboembolism), fibrinolytic disorders secondary to consumption coagulopathy, history of thromboembolic or coronary disease, history of seizure, liver failure, dyslipidemia, congenital coagulopathies (Von Willebrand Disease, Hemophilia A and B), acquired coagulopathy (Vitamin K deficiency, disseminated intravascular coagulation) and, thrombocytopenic purpura. Patients in whom postsurgical hemoglobin was not available, or patients who accidentally removed the drain or had leaks were eliminated from the study.

General anesthesia was given for all the procedures and surgery was performed by two seniors' surgeons with over 27 years of experience in spine surgery, standard posterior approach was utilized in all cases, and all the cases were treated with pedicle screw fixation, at least one osteotomy and posterolateral or interbody fusion were performed in all the cases. All cases have been randomly divided into 2 groups.

Interventions:

  1. Control group (n=30 cases): 100ml of water, and 3 tablets of placebo pills were administered 2 hours prior to surgery.
  2. PO TXA group (n=30 cases): Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision. The dose was administered by the nurse on duty who provided 100ml of water to swallow the pills.

For both groups estimation of intraoperative bleeding was calculated by the anesthesiologist at the end of the surgery, anesthesiologist and surgeons in charge were blinded to the patient group, the need for transfusion during surgery and the amount of volume to be transfused was determined by the anesthesiologist. A suction drain was placed deep into the fascia before closure; the amount of total drainage at 36 hours was recorded. The Suction drain was constantly kept in suction mode, and it was removed when the output was less than 100ml/24-hour period after postoperative day 1.

Post-operatory transfusion (within the first 48 hours after surgery) was carried out in patients with hemoglobin <8mg/dL and for patients with clinical symptoms of anemia such as hypotension and tachycardia.

Clinical data include age, height, weight, BMI, operative time, hemoglobin levels preoperatively and 24 hours postoperatively, number of spine levels operated, the volume of blood loss, calculated as intraoperative blood loss plus drainage collection total bleeding, number of transfusions received (units of transfusions received in the trans operative and postoperative period), length of stay and, the complication was also analyzed.

Statistical Analysis The qualitative data were presented as numbers and percentages. Kolmogorov-Smirnov test determined normality of the data. The parametric quantitate data were presented as mean and standard deviation. Comparison between groups was analyzed by using the x2 test or Fisher exact test for qualitative data, and the unparaided t-test for quantitative data. A logistic regression model that included the variables use of oral TXA, sex, BMI, age, number of levels operated, complication, and time of surgery (mean 230min) was performed.

A multivariate forward stepwise logistic regression model was then used to measure the adjusted association of these variables with intraoperative transfusion, with significance set at p<0.05. Data was analyzed using SPSS version 24.0 (IBM COrp, Armonk, NY).

Being tested
Tranexamic Acid Oral Product, Placebo pills

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tranexamic Acid Oral ProductDrug

    Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision.

  • Placebo pillsDrug

    Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.

Study groups in NCT05705336
Study groupRoleWhat they receive
1. Tranexamic Acid Oral Product (n=30 cases)Active comparatorSingle dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision. The dose was administered by the nurse on duty who provided 100ml of water to swallow the pills.
Receives: Drug: Tranexamic Acid Oral Product
2. Placebo (30 cases)Placebo comparatorNursery team would provide 100ml of water, and 3 tablets of placebo pills administered 2 hours prior to surgery.
Receives: Drug: Placebo pills

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total volume of blood loss

    Calculated as intraoperative blood loss plus drainage collection. It was calculated by the anesthesiologist at the end of the surgery, the anesthesiologist and surgeons in charge were blinded to the patient group. A suction drain was placed deep into the fascia before closure; the amount of total drainage was recorded.

    Measured: 48 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jan 2023
  2. Study start1 Jan 2021
  3. Primary completion30 Dec 2021
  4. Study completion1 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
2 randomized groups
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05705336
Sponsor's protocol ID
N0421
Status last verified
Jan 2023
First submitted
5 Jan 2023
Last updated
30 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Tranexamic Acid Oral Product in people with Tranexamic Acid (TXA) and Prospective Study, run by Alejandro Reyes Sánchez at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total volume of blood loss (time frame: 48 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in